Int J Rehabil Res., 2008; 31(3): 253-6,
Whole body vibration: a new therapeutic approach to improve muscle function in cystic fibrosis
Rietschel E, van Koningsbruggen S, Fricke O, Semler O, Schoenau E
CF-Center, Children”s Hospital, University of Cologne, Cologne, Germany. Ernst.Rietschel@uk-koeln.de
OBJECTIVE: Disease progression in cystic fibrosis (CF) leads to muscle wasting and loss of muscle function. The aim of this prospective pilot study was to evaluate the effects of whole body vibration (WBV) on muscle function in adult patients with CF.
PARTICIPANTS: Ten patients (three males; seven females) of the CF Center Cologne, Germany, have completed the 3-month study (age: 24-47 years; forced expiratory volume in 1 s (FEV1) 17-109% predicted (49+/-29) and body mass index (BMI) 16.6-24.4 kg/m2 (19.3+/-2.5). WBV was provided by a vibration platform (Galileo 2000).
METHOD: The patients were standing in an upright position receiving vertical vibration of frequencies between 20 and 25 Hz. The vibration exercise evokes muscle contractions via stretch reflexes improving muscular activity. The training schedule consisted of three 3-min sessions twice a day, 5 days per week for 3 months. Every 4 weeks the following tests were carried out: FEV1, forced vital capacity (FVC), BMI, chair-rising test (CRT), one-leg and two-leg jump test as well as maximal isometric grip force.
RESULTS: The study has been approved by the local ethics committee. After 3 months of WBV all parameters in the CRT significantly improved: chair-rising time (P=0.03), maximal force (P=0.02), maximal power (P=0.01) as well as velocity (P=0.02). The peak jump force (P=0.02) and velocity (P=0.01) of the two-leg jump significantly improved. Parameters in the one-leg jump as well as maximal isometric grip force showed no significant improvement. Weight and BMI showed a slightly positive trend whereas FEV1 and FVC did not significantly change. Any change in mechanographic parameters did not correlate with FEV1 or FVC in this study.
CONCLUSION: These results demonstrate that WBV can improve muscle function in CF patients.
Product groups: Galileo® Therapy Systems
Topics: Paediatrics, Neuronal Diseases, Medical Faculties, Physiotherapy & Rehabilitation, Therapy & Prevention with Galileo®